Mar­tin Shkre­li-as­so­ci­at­ed com­pa­nies set­tle an­ti-com­pet­i­tive law­suit with in­sur­er for $28M

One of Mar­tin Shkre­li’s last lega­cies in the phar­ma in­dus­try may be a $28 mil­lion set­tle­ment with an in­sur­ance net­work.

Al­most a year af­ter Blue Cross and Blue Shield of Min­neso­ta sued Shkre­li and Tur­ing-turned-Vy­era Phar­ma­ceu­ti­cals — along­side its Swiss par­ent com­pa­ny Phoenixus and CEO Kevin Mul­leady — al­leg­ing plans to cre­ate a mo­nop­oly over a life-sav­ing an­tipar­a­sitic, the par­ties have reached an agree­ment to re­solve the lit­i­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER